CA4-GFAP Binding to Reduce Neurodegenerative Protein Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to prevent and reduce protein aggregates that contribute to neurodegenerative diseases, as they are a common feature in conditions such as Alzheimer's, Parkinson's, and Huntington's diseases, and their formation is linked to the pathogenesis of these disorders.
Innovation Solution
Administering a composition comprising combretastatin-A4 (CA4) or its analogs to bind glial fibrillary acidic protein (GFAP) and other proteins, thereby reducing protein aggregates in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein aggregation is allowed to proceed naturally, then normal protein function is maintained, but neurodegenerative disease develops
Solution Approach 1:
The patent converts the harmful effect of protein aggregation into a beneficial therapeutic approach by using combretastatin-A4 to target and reduce aggregate formation. The compound binds to GFAP and other proteins, transforming the aggregation process from a disease-causing mechanism into a controlled therapeutic intervention that prevents neurodegeneration.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure and binding characteristics of combretastatin-A4 to optimize its affinity for GFAP and other aggregation-prone proteins. This chemical optimization enables the compound to effectively alter the aggregation parameters and prevent neurodegenerative disease progression.
2Reliability
If combretastatin-A4 is administered to bind GFAP and reduce protein aggregates, then neurodegenerative disease risk is reduced, but the compound must be specifically targeted to avoid off-effects
Solution Approach 1:
The patent applies local quality by designing combretastatin-A4 with specific binding characteristics that target GFAP and other aggregation-prone proteins in the central nervous system. The compound's chemical structure is optimized to provide selective affinity for these specific targets, enabling localized action in the brain while minimizing off-target effects in other tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly reduces protein aggregates, delaying the onset of neurodegenerative diseases, slowing their progression, and reversing symptoms, with potential applications in various animal species including humans.
Implementation Method 1
The CA4 analog may bind glial fibrillary acidic protein (GFAP)
Data Source
AI summary
The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).